Zhang Qingqing, Shi Dingwen, Guo Mengqin, Zhao Hao, Zhao Yanbing, Yang Xiangliang
National Engineering Research Center for Nanomedicine, Key Laboratory of Molecular Biophysics of Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan430074, People's Republic of China.
Hubei Key Laboratory of Bioinorganic Chemistry and Materia Medica, Hubei Engineering Research Center for Biomaterials and Medical Protective Materials, Huazhong University of Science and Technology, Wuhan430074, People's Republic of China.
ACS Nano. 2023 Jan 10;17(1):515-529. doi: 10.1021/acsnano.2c09242. Epub 2022 Dec 29.
Pyroptosis is gasdermin-mediated programmed necrosis that exhibits promising potential application in cancer immunotherapy, and the main challenge lies in how to provoke specific pyroptosis of tumor cells. Here, GC@PNA with a precisely stoichiometric ratio of Au(I) ion/Au(0) atom induced pyroptosis of tumor cells by its radiofrequency (RF)-heating effect. An / assay on 4T1 tumor cells indicates RF-activated pyroptosis of tumor cells elicits a robust ICD effect, enhancing the synergistic antitumor efficacy of GC@PNA with decitabine, significantly suppressing tumor metastasis and relapse by provoking systemic antitumor immune responses. Utilizing RF-activated pyroptotic immune responses, GC@PNA efficiently enhances the antitumor efficacy of αPD-1 immunotherapy under RF irradiation and provides a promising strategy for improving cancer immunotherapy by the noninvasive RF field with high clinical transformation potential.
细胞焦亡是由gasdermin介导的程序性坏死,在癌症免疫治疗中具有广阔的潜在应用前景,而主要挑战在于如何引发肿瘤细胞的特异性焦亡。在此,具有精确化学计量比的金(I)离子/金(0)原子的GC@PNA通过其射频(RF)加热效应诱导肿瘤细胞焦亡。对4T1肿瘤细胞的一项分析表明,射频激活的肿瘤细胞焦亡引发了强大的免疫原性细胞死亡(ICD)效应,增强了GC@PNA与地西他滨的协同抗肿瘤疗效,通过激发全身抗肿瘤免疫反应显著抑制肿瘤转移和复发。利用射频激活的焦亡免疫反应,GC@PNA在射频照射下有效增强了αPD-1免疫治疗的抗肿瘤疗效,并为通过具有高临床转化潜力的非侵入性射频场改善癌症免疫治疗提供了一种有前景的策略。
Semin Immunol. 2023-7
J Mater Chem B. 2024-4-24
Biomater Sci. 2023-3-14
Theranostics. 2025-7-25
J Nanobiotechnology. 2025-7-21
Acta Pharm Sin B. 2025-2
J Immunother Cancer. 2025-2-25
Int J Nanomedicine. 2024
Int J Nanomedicine. 2024-4-8